ID

30370

Beschreibung

https://clinicaltrials.gov/ct2/show/NCT00486954 Study ID: 104578 Clinical Study ID: EGF104578 Study Title: A Randomized, Multicenter, Open-label, Phase III Study of Lapatinib (GW572016) in Combination with weekly Paclitaxel versus weekly Paclitaxel alone in the second line treatment of ErbB2 amplified Advanced Gastric Cancer Patient Level Data: Clinicaltrials.gov Identifier: NCT00486954 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 3 Study Recruitment Status: Product Sponsorship Transferred to Novartis Generic Name: lapatinib Trade Name: Tyverb,Tykerb,Tycerb Study Indication: Neoplasms, Gastrointestinal Tract CRF Seiten: 1288-1609

Link

https://clinicaltrials.gov/ct2/show/NCT00486954

Stichworte

Versionen (1)
  1. 30.05.18 30.05.18 - Halim Ugurlu
Rechteinhaber

GlaxoSmithKline (GSK)

Hochgeladen am

30. Mai 2018

DOI

Für eine Beantragung loggen Sie sich ein.

Lizenz

Creative Commons BY-NC 3.0
Modell Kommentare :

Hier können Sie das Modell kommentieren. Über die Sprechblasen an den Itemgruppen und Items können Sie diese spezifisch kommentieren.

Zurück zu Modell Kommentaren
Itemgroup Kommentare für :

Item Kommentare für :

Um Formulare herunterzuladen müssen Sie angemeldet sein. Bitte loggen Sie sich ein oder registrieren Sie sich kostenlos.

NCT00486954_Lapatinib in Combination With Weekly Paclitaxel in Patients With ErbB2 Amplified Advanced Gastric Cancer

Englisch

Investigational Product Compliance-Lapatinib, Investigational Product Discontinuation

1 Formulare  
Investigational Product Compliance-Lapatinib
Beschreibung

Investigational Product Compliance-Lapatinib

Alias
UMLS CUI-1
C0304229
UMLS CUI-2
C1321605
Date Investigational Product dispensed
Beschreibung

Date Investigational Product dispensed

Datentyp

date

Alias
UMLS CUI [1,1]
C0011008
UMLS CUI [1,2]
C0947323
UMLS CUI [1,3]
C0304229
Total Number Dispensed
Beschreibung

Total Number Dispensed

Datentyp

text

Alias
UMLS CUI [1,1]
C0805077
UMLS CUI [1,2]
C0304229
Date investigatinal Product returned
Beschreibung

Date investigatinal Product returned

Datentyp

date

Alias
UMLS CUI [1,1]
C0013230
UMLS CUI [1,2]
C2826249
Total number returned
Beschreibung

Total number returned

Datentyp

text

Alias
UMLS CUI [1,1]
C2699071
UMLS CUI [1,2]
C0039225
Investigational Product Discontinuation
Beschreibung

Investigational Product Discontinuation

Alias
UMLS CUI-1
C0304229
UMLS CUI-2
C0457454
Investigational Product
Beschreibung

Investigational Product

Datentyp

integer

Alias
UMLS CUI [1]
C0304229
Was the investigational product stopped permanently before the end of the scheduled treatment period?
Beschreibung

Investigational product stopped permanently before the end of the scheduled treatment period

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0304229
UMLS CUI [1,2]
C0457454
If yes, specify the primary reason the investigational product was stopped
Beschreibung

Specify the primary reason the investigational product was stopped

Datentyp

integer

Alias
UMLS CUI [1,1]
C0392360
UMLS CUI [1,2]
C0304229
UMLS CUI [1,3]
C0457454
Zum Seitenanfang zurückkehren

Ähnliche Modelle

Investigational Product Compliance-Lapatinib, Investigational Product Discontinuation

1 Formulare
Name
Typ
Description | Question | Decode (Coded Value)
Datentyp
Alias
Item Group
Investigational Product Compliance-Lapatinib
C0304229 (UMLS CUI-1)
C1321605 (UMLS CUI-2)
Date Investigational Product dispensed
Item
Date Investigational Product dispensed
date
C0011008 (UMLS CUI [1,1])
C0947323 (UMLS CUI [1,2])
C0304229 (UMLS CUI [1,3])
Total Number Dispensed
Item
Total Number Dispensed
text
C0805077 (UMLS CUI [1,1])
C0304229 (UMLS CUI [1,2])
Date investigatinal Product returned
Item
Date investigatinal Product returned
date
C0013230 (UMLS CUI [1,1])
C2826249 (UMLS CUI [1,2])
Total number returned
Item
Total number returned
text
C2699071 (UMLS CUI [1,1])
C0039225 (UMLS CUI [1,2])
Item Group
Investigational Product Discontinuation
C0304229 (UMLS CUI-1)
C0457454 (UMLS CUI-2)
Item
Investigational Product
integer
C0304229 (UMLS CUI [1])
Investigational Product
Code List
Investigational Product
CL Item
Lapatinib (1)
CL Item
Paclitaxel (2)
Investigational product stopped permanently before the end of the scheduled treatment period
Item
Was the investigational product stopped permanently before the end of the scheduled treatment period?
boolean
C0304229 (UMLS CUI [1,1])
C0457454 (UMLS CUI [1,2])
Item
If yes, specify the primary reason the investigational product was stopped
integer
C0392360 (UMLS CUI [1,1])
C0304229 (UMLS CUI [1,2])
C0457454 (UMLS CUI [1,3])
Specify the primary reason the investigational product was stopped
Code List
If yes, specify the primary reason the investigational product was stopped
CL Item
Adverse evetn, record details on the Non-Serious Adverse Events or Serious Adverse Events forms as appropriate (1)
CL Item
Lost to follow-up (2)
CL Item
Protocol violation (3)
CL Item
Subject decided to withdraw from the study (4)
CL Item
Sponsor termined study (6)
CL Item
Disease progression (7)
CL Item
Death (25)
CL Item
Subject decided to withdraw from IP but is to be followed for survival per protocol (27)
CL Item
Other, Specify (0)
Zum Seitenanfang zurückkehren 

Kontakt

Benutzen Sie dieses Formular für Rückmeldungen, Fragen und Verbesserungsvorschläge.

Mit * gekennzeichnete Felder sind notwendig.

Hilfe

Benötigen Sie Hilfe bei der Suche? Um mehr Details zu erfahren und die Suche effektiver nutzen zu können schauen Sie sich doch das entsprechende Video auf unserer Tutorial Seite an.

Zum Video